

Supplemental table 1. Antibodies and conditions used for immunohistochemistry

Antibody	Manufacturer	Dilution	Incubation Time (minutes)	Antigen Retrieval
GCET1	Gift*	1:1	30	EDTA 10
CD10	Ventana	RTU	32	CC1
BCL6	Dako	RTU	30	FLEX
MUM1	Dako	1:800	20	FLEX
FOXP1	Gift**	1:80	30	EDTA 30
SPARC	Santa Cruz	1:100	30	Citrate
CD31	Dako	1:40	30	Citrate-1

RTU, ready to use; EDTA 10 minutes, 1 mmol/L EDTA, pH 8.0, 10 minutes at 115°C; CC1, cell conditioning solution for antigen unmasking (Ventana); FLEX, Envision Flex high pH visualization system (Dako); EDTA 30 minutes, 1 mmol/L EDTA, pH 8.0, 30 minutes at 95°C; Citrate, 10 mmol/L citrate, pH 6.0, 60 minutes at 95°C; Citrate-1, pH 6.0, 20 minutes

*Kindly donated by Miguel Piris, Lymphoma Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain (available from Abcam); **kindly donated by Alison Banham, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom (available from Invitrogen)

Supplemental table 2. Clinical features of all patients and those used or not used to build the training set for the biological prognostic model.

	Total (n = 235)		Prognostic Model (n = 125)		Cases not Used (n = 110)		P
	N	%	N	%	N	%	
Male	136	58	70	56	66	60	0.54
Age							
< 60 years	117	50	57	46	60	55	0.17
≥ 60 years	118	50	68	54	50	45	
Stage							
I/II	106	48	55	47	51	49	0.76
III/IV	115	52	62	53	53	51	
Missing	14	-	8	-	6	-	
No. of extranodal sites							
< 2	171	84	90	85	81	83	0.66
≥ 2	33	16	16	15	17	17	
Missing	31	-	19	-	12	-	
Serum LDH							
Normal	96	51	49	46	47	57	0.14
Elevated	94	49	58	54	36	43	
Missing	45	-	18	-	27	-	
Performance score							
> 70	160	77	94	81	66	72	0.11
≤ 70	48	23	22	19	26	28	
Missing	27	-	9	-	18	-	
IPI score							
Low (0-2)	125	66	69	66	56	66	0.95
High (3-5)	64	34	35	34	29	34	
Missing	46	-	21	-	25	-	
5-year OS		65		63		70	0.40
5-year EFS		59		54		66	0.16

LDH, lactate dehydrogenase; IPI, International Prognostic Index; OS, overall survival; EFS, event-free survival

Supplemental table 3. Calibration of the biological prognostic model

Time point	Risk group	Overall Survival		Event-free Survival	
		Predicted probability	Observed probability (95% CI)	Predicted probability	Observed probability (95% CI)
1-year	0-1	0.93	0.94 (0.82-0.98)	0.90	0.81 (0.67-0.90)
	2-3	0.74	0.84 (0.63-0.94)	0.58	0.60 (0.38-0.76)
2-years	0-1	0.86	0.86 (0.72-0.93)	0.82	0.75 (0.60-0.85)
	2-3	0.55	0.68 (0.46-0.83)	0.46	0.56 (0.34-0.73)
3-years	0-1	0.84	0.86 (0.72-0.93)	0.70	0.75 (0.60-0.85)
	2-3	0.53	0.48 (0.28-0.66)	0.43	0.39 (0.20-0.57)
5-years	0-1	0.73	0.79 (0.65-0.88)	0.62	0.72 (0.58-0.83)
	2-3	0.49	0.44 (0.24-0.62)	0.43	0.34 (0.17-0.53)

CI, confidence interval